# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Georgia O'Keeffe (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET011-SYN-TD
- Date: 1968-04-09
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wendell Ashby, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week retina visit and second loading injection, left eye. **S**

## History of present illness

Ms. O'Keeffe returns four weeks after her first aflibercept injection. Lines on her canvases look less bent with the left eye, and the gray spot is smaller. She had a small red patch on the white of the eye after the injection that faded within a week, and no pain, redness, or loss of vision. Her daily Amsler checks show no change in the right eye. She takes the AREDS2 supplement every day and is still painting daily. **S**

| Element | Detail |
|---|---|
| Interval change | Less distortion and a smaller central spot in the left eye |
| After the first injection | Small red patch on the white of the eye that faded within a week; no pain or vision loss |
| Amsler grid | Daily checks; right eye unchanged |
| Adherence | AREDS2 supplement daily |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Milder distortion in the left eye; no pain, light sensitivity, flashes, or floaters |
| Constitutional | Negative | No fatigue or weight change |
| Psychiatric | Negative | Encouraged by the change; sleeping well |

3 systems reviewed. **S**

## Current medications

- No current medications. **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/72 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 55.5 kg; BMI 20.4 kg/m². All vital signs are synthetic.

Best-corrected visual acuity, left eye (ETDRS letters): 64 (low); Central subfield thickness by OCT, left eye: 322 um (high); Intraocular pressure, left eye: 15 mmHg. All results are synthetic.

## Change since baseline

- Best-corrected visual acuity, left eye (ETDRS letters): 56 (low) at baseline, 64 (low) at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| Visual acuity | Best-corrected 64 letters left, up from 55 |
| Intraocular pressure | 15 mmHg left before injection |
| Anterior segment | Quiet; no inflammation after the first injection |
| Dilated fundus, left eye | Lesion smaller, with less subretinal fluid |
| Dilated fundus, right eye | Large drusen unchanged; no fluid or hemorrhage |
| OCT, left eye | Residual subretinal fluid; central subfield thickness 322 µm, down from 418 |
| After injection, left eye | Optic nerve head perfused; counts fingers; no pain |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Neovascular age-related macular degeneration, left eye, responding** (H35.3221). Gain of 9 letters (55 to 64) and central subfield thickness down from 418 to 322 µm, with residual fluid. Second loading injection given today without complication. **S**
   - Third loading injection in four weeks.
   - Same-day call for warning signs.
2. **Intermediate dry age-related macular degeneration, right eye** (H35.3112). Stable on dilated examination; no new distortion. **S**
   - Continue the AREDS2 supplement and daily Amsler checks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Best-corrected visual acuity (ETDRS letters) | Every injection visit | Completed today | Left 64 letters, up 9 from baseline. The right eye is followed by Amsler grid and dilated examination during loading |
| Imaging | Optical coherence tomography of the macula | Every injection visit | Completed today | Left eye: central subfield thickness 322 µm with residual fluid |
| Examination | Intraocular pressure before and after injection | Every injection visit | Completed today | Before injection 15 mmHg left; after injection, optic nerve perfused and counting fingers |
| Imaging | Fluorescein angiography or OCT angiography | If the response is poor or the picture atypical | Not indicated | Responding as expected to loading, which supports the diagnosis |
| Examination | Dilated examination of the fellow (right) eye | Every injection visit | Completed today | Large drusen unchanged; no fluid |
| Medication safety | Intravitreal injection safety | Every injection visit | Completed today | Small subconjunctival hemorrhage after the first injection, resolved; no inflammation. Second loading dose today |
| Self-management | Teaching on warning signs of endophthalmitis and retinal detachment | Every injection visit | Completed today | Reviewed again |
| Self-management | Daily home Amsler grid, each eye | Daily | Completed today | Daily checks recorded; no change in the right eye |
| Medication safety | AREDS2 supplement for intermediate AMD | Daily, long term | Completed today | Taking it daily |
| Referral | Low-vision rehabilitation, with home fall-risk review and a driving assessment | Once central vision is reduced; review as vision changes | Referred | Evaluation booked for next month |
| Survey | Depression screen (PHQ-2) | At follow-up, because vision loss raises the risk of depression; periodically at 65 or older | Due | Planned at the July primary care review |

## Goal progress

- Gain at least 10 ETDRS letters in the left eye by the end of the loading phase. In progress; target 1968-05-07. **S**
- Dry macula on OCT (central subfield thickness below 300 um, no fluid) by the end of the loading phase. In progress; target 1968-05-07. **S**
- Check the Amsler grid daily for each eye and report any change the same day. In progress; target 1968-07-02. **S**
- Complete a low-vision rehabilitation evaluation and set up studio lighting and magnification by the July visit. In progress; target 1968-07-02. **S**

## Guideline basis

- Age-Related Macular Degeneration Preferred Practice Pattern (2024), American Academy of Ophthalmology
- CMID: Clinical Monitoring Intelligence Database, cataract and glaucoma monographs (eye-examination items) (2026), Aether Forge

## Follow-up

- Retina visit in four weeks for the third loading injection. **S**
- Next scheduled visit 1968-05-07: eight-week retina follow-up with OCT and third injection. **S**
